NDA 021912 · Lupin
Brovana
Arformoterol Tartrate · Inhalation
DiscontinuedLast checked: Nov 20, 2026Latest source record: May 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Oct 6, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
514
215 Phase 3, 21 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 27, 2014 Supplement 23 · Efficacy LabelMedication GuideLetter
- Oct 6, 2006 Original approval · Type 3 - New Dosage Form Other Important Information from FDALabelReview
1 products under this application
- BROVANA · ARFORMOTEROL TARTRATE EQ 0.015MG BASE/2ML · SOLUTION, INHALATION · Discontinued · TE AN
Clinical trials
Interventional ClinicalTrials.gov studies with "Arformoterol" as an intervention, any sponsor and status, largest first.
- A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and AdolescentsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01444430 · 12,460 participants · Start Dec 2011 · Primary completion Oct 2015
Drug: Symbicort pMDI; budesonide pMDI · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Anchorage, Alaska · 340 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02465567 · 8,588 participants · Start Jun 30, 2015 · Primary completion Jul 26, 2019
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 741 sites in all
- Local Phase 4 Pan-European SMART StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00463866 · 8,424 participants · Start Mar 2007
Drug: Budesonide/formoterol · For: Asthma
Sites: Aalst, Belgium; Aarschot, Belgium; Aatrijken, Belgium · 817 sites in all
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02224157 · 4,215 participants · Start Nov 28, 2014 · Primary completion Aug 16, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; budesonode bid + terbutaline 'as needed' · For: Asthma
Sites: Sydney, Australia; Botucatu, Brazil; Florianópolis, Brazil · 340 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02149199 · 3,850 participants · Start Jul 7, 2014 · Primary completion Aug 2, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; terbutaline 'as needed' + placebo budesonide bid and 1 more · For: Asthma
Sites: Bedford Park, Australia; Concord, Australia; Maroubra, Australia · 255 sites in all
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01911364 · 3,686 participants · Start Jan 2014 · Primary completion Mar 2016
Drug: BDP/FF/GB; Tiotropium and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Hessen, Germany; Szeged, Hungary; Perugia, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Brovana (Arformoterol Tartrate)
2024 spending
$146K
Beneficiaries
49
333 claims
Per beneficiary
$2,972
$4.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $145,625 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The safety and efficacy of arformoterol and formoterol in COPD.
Hanania NA, Donohue JF, Nelson H, et al. · COPD 2010 · Multicenter Study, Randomized Controlled Trial
- Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.
Hanrahan JP, Hanania NA, Calhoun WJ, et al. · COPD 2008 · Clinical Trial, Phase III, Comparative Study
- Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
Donohue JF, Bollu VK, Stull DE, et al. · Int J Chron Obstruct Pulmon Dis 2018 · Clinical Trial, Phase III, Multicenter Study
- Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA, Waterman LA, Ward J, et al. · J Aerosol Med Pulm Drug Deliv 2014 · Comparative Study, Randomized Controlled Trial
- One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.
Donohue JF, Hanania NA, Make B, et al. · Chest 2014 · Multicenter Study, Randomized Controlled Trial
- Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Donohue JF, Hanania NA, Sciarappa KA, et al. · Ther Adv Respir Dis 2008 · Multicenter Study, Randomized Controlled Trial
Sponsor: Lupin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.